drugset
drugset / Trial / NCT01555268

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT01555268 ↗

Phase 1 Completed 24 enrolled Roswell Park Cancer Institute Amgen · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and the best dose of trebananib when given together with or without low-dose cytarabine in treating patients with acute myeloid leukemia (AML). Trebananib may stop the growth of AML by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving trebananib together with cytarabine may be an effective treatment for patients with AML.

Timeline

Start
2011-10-31
Primary completion
2013-09-24
Completion
2016-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule — Subcutaneous
Subject Trebananib Peptide — Intravenous

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 adult acute monocytic leukemia